Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

• Published in: Respiratory medicine case reports Vol. 30; p. 101063
• Main Authors: Horowitz, Richard I., Freeman, Phyllis R., Bruzzese, James
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-01-2020; Elsevier
• Subjects: ARDS; Case Report; COVID 19; Glutathione; N-acetyl-cysteine; NF-κB; Pneumonia; NF-κB; Pneumonia; N-acetyl-cysteine; COVID 19; ARDS; Glutathione
• ISSN: 2213-0071; 2213-0071
• DOI: 10.1016/j.rmcr.2020.101063

Infection with COVID-19 potentially can result in severe outcomes and death from “cytokine storm syndrome”, resulting in novel coronavirus pneumonia (NCP) with severe dyspnea, acute respiratory distress syndrome (ARDS), fulminant myocarditis and multiorgan dysfunction with or without disseminated intravascular coagulation. No published treatment to date has been shown to adequately control the inflammation and respiratory symptoms associated with COVID-19, apart from oxygen therapy and assisted ventilation. We evaluated the effects of using high dose oral and/or IV glutathione in the treatment of 2 patients with dyspnea secondary to COVID-19 pneumonia.
Two patients living in New York City (NYC) with a history of Lyme and tick-borne co-infections experienced a cough and dyspnea and demonstrated radiological findings consistent with novel coronavirus pneumonia (NCP). A trial of 2 g of PO or IV glutathione was used in both patients and improved their dyspnea within 1 h of use. Repeated use of both 2000 mg of PO and IV glutathione was effective in further relieving respiratory symptoms.
Oral and IV glutathione, glutathione precursors (N-acetyl-cysteine) and alpha lipoic acid may represent a novel treatment approach for blocking NF-κB and addressing “cytokine storm syndrome” and respiratory distress in patients with COVID-19 pneumonia.